Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Systemic reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Any adverse event

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Serious adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Local reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

mRNA‐1273 – ModernaTX vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28451 participants
High

Booster vs placebo/no booster

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Booster vs placebo/no booster

Confirmed symptomatic COVID‐19b

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Booster vs placebo/no booster

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Booster vs placebo/no booster

All‐cause mortalityb

It is very uncertain whether booster changes all‐cause mortalityb compared with placebo/no booster (very low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.27 [0.52, 3.05]
1 study · 28254 participants
Very low

Booster vs placebo/no booster

Systemic reactogenicity events

Booster showed no clear difference in systemic reactogenicity eventsf compared with placebo/no booster (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.8 [0.71, 4.56]
1 study · 119 participants
Low

Booster vs placebo/no booster

Any adverse event

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Booster vs placebo/no booster

Serious adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Booster vs placebo/no booster

Local reactogenicity events

Booster probably leads to higher local reactogenicity eventsf compared with placebo/no booster (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 6.46 [3.18, 13.13]
1 study · 119 participants
Moderate

mRNA‐1273 – ModernaTX vs placebo

All‐cause mortalityf

mRNA‐1273 – ModernaTX showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.06 [0.54, 2.1]
1 study · 30346 participants
Low

mRNA‐1273 – ModernaTX vs placebo

Systemic reactogenicity events

mRNA‐1273 – ModernaTX leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.28 [1.22, 1.34]
2 studies · 34037 participants
High

mRNA‐1273 – ModernaTX vs placebo

Any adverse eventk

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32995 participants
Low

mRNA‐1273 – ModernaTX vs placebo

Serious adverse eventsl

mRNA‐1273 – ModernaTX showed no clear difference in serious adverse eventsl compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.92 [0.78, 1.08]
2 studies · 34072 participants
Moderate

mRNA‐1273 – ModernaTX vs placebo

Local reactogenicity events

mRNA‐1273 – ModernaTX leads to higher local reactogenicity eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 3.3 [2.02, 5.4]
2 studies · 34037 participants
High

CVnCoV – CureVac AG vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CVnCoV – CureVac AG vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25062 participants
Moderate